Apart from that, suppression of sorafenib causes hypoxic response to be converted from HIF-1α to HIF-2α-dependent pathways, thereby promoting sorafenib resistance in hypoxic HCC cells. The gene discussed is EPAS1; the disease is hepatocellular carcinoma.